Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin

Molecular Biology of the Cell

Volumn 17, Issue 4, 2006, Pages 1652-1663

  Benchoua, Alexandra ^a   Trioulier, Yaël ^a   Zala, Diana ^b   Gaillard, Marie Claude ^c   Lefort, Nathalie ^d   Dufour, Noelle ^a   Saudou, Frederic ^e   Elalouf, Jean Marc ^c   Hirsch, Etienne ^f   Hantraye, Philippe ^a   Déglon, Nicole ^a   Brouillet, Emmanuel ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b EPFL   (Switzerland)

^c CEA SACLAY   (France)

^d INSERM   (France)

^e CNRS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVINE ADENINE NUCLEOTIDE; HUNTINGTIN; IRON; LENTIVIRUS VECTOR; MESSENGER RNA; MUTANT PROTEIN; OXIDOREDUCTASE; POLYGLUTAMINE; PROTEIN SUBUNIT; SUCCINATE DEHYDROGENASE (UBIQUINONE); SULFUR; HD PROTEIN, HUMAN; IRON SULFUR PROTEIN; MITOCHONDRIAL PROTEIN; NERVE PROTEIN; NUCLEAR PROTEIN; PEPTIDE; SDHA PROTEIN, HUMAN; SDHB PROTEIN, HUMAN; SUCCINATE DEHYDROGENASE;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; NERVE CELL NECROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; APOPTOSIS; CYTOLOGY; DOWN REGULATION; ENZYMOLOGY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; LENTIVIRINAE; METABOLISM; MITOCHONDRION; MUTAGENESIS; MUTATION; NERVE CELL;

APOPTOSIS; CORPUS STRIATUM; DOWN-REGULATION; ELECTRON TRANSPORT COMPLEX II; GENETIC VECTORS; HUMANS; HUNTINGTON DISEASE; IRON-SULFUR PROTEINS; LENTIVIRUS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MUTAGENESIS; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PEPTIDES; PROTEIN SUBUNITS; SUCCINATE DEHYDROGENASE; TRANSFECTION;

EID: 33745392939     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E05-07-0607     Document Type: Article

References (60)

1. Ackrell, B. A. (2000). Progress in understanding structure-function relationships in respiratory chain complex II. FEBS Lett. 466, 1-5.
2. Bae, B. I. et al. (2005). p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29-41.
3. Beal, M. F. (1992). Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 32, 119-130.
4. Benchoua, A., Braudeau, J., Reis, A., Couriaud, C., and Onteniente, B. (2004). Activation of proinflammatory caspases by cathepsin B in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 24, 1272-1279.
5. Benchoua, A., Couriaud, C., Guegan, C., Tartier, L., Couvert, P., Friocourt, G., Chelly, J., Menissier-de Murcia, J., and Onteniente, B. (2002). Active caspase-8 translocates into the nucleus of apoptotic cells to inactivate poly(ADP-ribose) polymerase-2. J. Biol. Chem. 277, 34217-34222.
6. Benchoua, A., Guegan, C., Couriaud, C., Hosseini, H., Sampaio, N., Morin, D1,. and Onteniente, B. (2001). Specific caspase pathways are activated in the two stages of cerebral infarction. J. Neurosci. 21, 7127-7134.
7. Bezprozvanny, I., and Hayden, M. R. (2004). Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322, 1310-1317.
8. Bizat, N., Hermel, J. M., Boyer, F., Jacquard, C., Creminon, C., Ouary, S., Escartin, C., Hantraye, P., Kajewski, S., Brouillet, E. (2003). Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J. Neurosci. 23, 5020-5030.
9. Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Pequignot, E., Munnich, A., and Rotig, A. (1995). Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat. Genet. 11, 144-149.
10. Brennan, W. A., Jr., Bird, E. D., and Aprille, J. R. (1985). Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 44, 1948-1950.
11. Brouillet, E., Conde, F., Beal, M. F., and Hantraye, P. (1999). Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59, 427-468.
12. Brouillet, E., Jacquard, C., Bizat, N., and Blum, D. (2005). 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95, 1521-1540.
13. Browne, S. E., Bowling, A. C., MacGarvey, U., Baik, M. J., Berger, S. C., Muqit, M. M., Bird, E. D., and Beal, M. F. (1997). Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653.
14. Butterworth, N. J., Willians, L., Bullock, J. Y., Love, D. R., Faull, R.L.M., and Dragunow, M. (1998). Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 87, 49-53.
15. Butterworth, J., Yates, C. M., and Reynolds, G. P. (1985). Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J. Neurol. Sci. 67, 161-171.
16. Chipuk, J. E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D. D., and Green, D. R. (2005). PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309, 1732-1735.
17. Chomczynski, P., and Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
18. Choo, Y. S., Johnson, G. V., MacDonald, M., Detloff, P. J., and Lesort, M. (2004). Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 1407-1420.
19. Culmsee, C., and Mattson, M. P. (2005). p53 in neuronal apoptosis. Biochem. Biophys. Res. Commun. 331, 761-777.
20. de Almeida, L. P., Ross, C. A., Zala, D., Aebischer, P., and Deglon, N. (2002). Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 22, 3473-3483.
21. Deglon, N., Tseng, J. L., Bensadoun, J. C., Zurn, A. D., Arsenijevic, Y., de Almeida, L., Zufferey, R., Trono, D., and Aebischer, P. (2000). Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene. Ther. 11, 179-190.
22. Gilmore, K., and Wilson, M. (1999). The use of chloromethyl-X-rosamine (Mitotracker red) to measure loss of mitochondrial membrane potential in apoptotic cells is incompatible with cell fixation. Cytometry 36, 355-358.
23. Gimenez-Roqueplo, A. P., Favier, J., Rustin, P., Mourad, J. J., Plouin, P. F., Corvol, P., Rotig, A., and Jeunemaitre, X. (2001). The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 69, 1186-1197.
24. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547-5551.
25. Gourfinkel-An, I., Vila, M., Faucheux, B., Duyckaerts, C., Viallet, F., Hauw, J. J., Brice, A., Agid, Y., and Hirsch, E. C. (2002). Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J. Neurochem. 80, 466-476.
26. Gray, N. K., Pantopoulos, K., Dandekar, T., Ackrell, B. A., and Hentze, M. W. (1996). Translational regulation of mammalian and Drosophila citric acid cycle enzymes via iron-responsive elements. Proc. Natl. Acad. Sci. USA 93, 4925-4930.
27. Gu, M., Gash, M. T., Mann, V. M., Javoy-Agid, F., Cooper, J. M., and Schapira, A. H. (1996). Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385-389.
28. Guo, B., Phillips, J. D., Yu, Y., and Leibold, E. A. (1995). Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J. Biol. Chem. 270, 21645-21651.
29. Heyne, K., Mannebach, S., Wuertz, E., Knaup, K. X., Mahyar-Roemer, M., and Roemer, K. (2004). Identification of a putative p53 binding sequence within the human mitochondrial genome. FEBS Lett. 578, 198-202.
30. Hilditch-Maguire, P., Trettel, F., Passani, L. A., Auerbach, A., Persichetti, F., and MacDonald, M. E. (2000). Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 9, 2789-2797.
31. Jana, N. R., Zemskov, E. A., Wang, G., and Nukina, N. (2001). Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10, 1049-1059.
32. Jenkins, B.G., Rosas, H. D., Chen, Y. C., Makabe, T., Myers, R., MacDonald, M., Rosen, B. R., Beal, M. F., and Koroshetz, W. J. (1998). 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 50, 1357-1365.
33. Kalbacova, M., Vrbacky, M., Drahota, Z., and Melkova, Z. (2003). Comparison of the effect of mitochondrial inhibitors on mitochondrial membrane potential in two different cell lines using flow cytometry and spectrofluorometry. Cytometry A 52, 110-116.
34. Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., and Beal, M. F. (1997). Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41, 160-165.
35. Lesort, M., Chun, W., Tucholski, J., and Johnson, G. V. (2002). Does tissue transglutaminase play a role in Huntington's disease? Neurochem. Int. 40, 37-52.
36. Li, S. H., and Li, X. J. (2004). Huntingtin and its role in neuronal degeneration. Neuroscientist 10, 467-475.
37. Lodi, R., Schapira, A. H., Manners, D., Styles, P., Wood, N. W., Taylor, D. J., and Warner, T. T. (2000). Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 48, 72-76.
38. Mann, V. M., Cooper, J. M., Javoy-Agid, F., Agid, Y., Jenner, P., and Schapira, A. H. (1990). Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336, 749.
39. Meriin, A. B., and Sherman, M. Y. (2005). Role of molecular chaperones in neurodegenerative disorders. Int. J. Hyperthermia 21, 403-419.
40. Munujos, P., Coll-Canti, J., Gonzalez-Sastre, F., and Gella, F. J. (1993). Assay of succinate dehydrogenase activity by a colorimetric-continuous method using iodonitrotetrazolium chloride as electron acceptor. Anal. Biochem. 212, 506-509.
41. Panov, A. V., Gutekunst, C. A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., and Greenamyre, J. T. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731-736.
42. Parfait, B., Chretien, D., Rotig, A., Marsac, C., Munnich, A., and Rustin, P. (2000). Compound heterozygous mutations in the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome. Hum. Genet. 106, 236-243.
43. Pendergrass, W., Wolf, N., and Poot, M. (2004). Efficacy of MitoTracker Green and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues. Cytometry A 61, 162-169.
44. Portera-Caillau, C., Hedreen, J. C., Price, D. L., and Koliatsos, V. E. (1995). Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15, 3775-3787.
45. Regulier, E., Pereira de Almeida, L., Sommer, B., Aebischer, P., and Deglon, N. (2002). Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum. Gene Ther. 13, 1981-1990.
46. Regulier, E., Trottier, Y., Perrin, V., Aebischer, P., and Deglon, N. (2003). Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striarum. Hum. Mol. Genet. 12, 2827-2836.
47. Ruan, Q., Lesort, M., MacDonald, M. E., and Johnson, G. V. (2004). Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum. Mol. Genet. 13, 669-681.
48. Rustin, P., Munnich, A., and Rotig, A. (2002). Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. Eur. J. Hum. Genet. 10, 289-291.
49. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M. E. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
50. Sawa, A., Wiegand, G. W., Cooper, J., Margolis, R. L., Sharp, A. H., Lawler, J. F., Jr., Greenamyre, J. T., Snyder, S. H., and Ross, C. A. (1999). Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5, 1194-1198.
51. Schilling, G. et al (1999). Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407.
52. Sugars, K. L., and Rubinsztein, D. C. (2003). Transcriptional abnormalities in Huntington disease. Trends Genet. 19, 233-238.
53. Tabrizi, S. J., Cleeter, M. W., Xuereb, J., Taanman, J. W., Cooper, J. M., and Schapira, A. H. (1999). Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45, 25-32.
54. The Huntington's Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
55. Thomas, L. B., Gates, D. J., Richfield, E. K., O'Brien, T. F., Schweitzer, J. B., and Steindler, D. A. (1995). DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp. Neurol. 133, 265-272.
56. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., and Richardson, E. P., Jr. (1985). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577.
57. Waelter, S., Boeddrich, A., Lurz, R., Scherzinger, E., Lueder, G., Lehrach, H., and Wanker, E. E. (2001). Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell 12, 1393-1407.
58. Wellington, C. L. et al. (2002). Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22, 7862-7872.
59. Zala, D., Benchoua, A., Brouillet, E., Zurn, A. D., Aebischer, P., and Déglon, N. (2005). Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding mutant huntingtin fragment. Neurobiol. Dis. 20, 785-798.
60. Zuccato, C. et al. (2003). Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76-83.